百时美施贵宝钱江：做不被定义的创新探路者

Core Viewpoint - The article highlights the transformative journey of the Chinese pharmaceutical industry from "catching up" to "leading," exemplified by the career of Qian Jiang, who has witnessed and contributed to significant changes over three decades [4][6]. Group 1: Career Development and Industry Changes - Qian Jiang's career reflects the evolution of the Chinese pharmaceutical sector, transitioning from a time when patients waited 8-10 years for innovative drugs to a present where rapid advancements are being made [1][4]. - The pharmaceutical industry in China is experiencing a shift towards innovation, with Qian emphasizing the importance of embracing change and technology, particularly artificial intelligence, to enhance efficiency and speed in drug development [8][9]. - The average time for scientific innovation to reach clinical application remains at 17 years, highlighting a significant gap that the industry aims to close [8]. Group 2: Personal Philosophy and Leadership - Qian Jiang views himself as a "fortunate child of the era," attributing his career advancements to the broader changes in the pharmaceutical landscape [3][11]. - His leadership philosophy centers on the idea that the role of pharmaceutical executives has evolved from mere management to becoming pioneers who connect global and local innovation ecosystems [14][15]. - The commitment to patient-centered care is a core value for Qian, emphasizing that the ultimate goal of pharmaceutical work is to improve patients' lives [19][20]. Group 3: Strategic Vision for BMS - BMS China aims to leverage its long-standing presence and adapt to the changing pharmaceutical ecosystem by fostering innovation and collaboration [15][16]. - The company’s strategy includes a commitment to delivering innovative drugs more rapidly to patients, reflecting a long-term vision for growth and value creation [16][24]. - Qian Jiang's experience in both multinational corporations and local biotech firms positions him uniquely to drive BMS's strategic initiatives in China [13][14].